| 產品名稱 | HEY-T30 |
|---|---|
| 商品貨號 | B197879 |
| Organism | Homo sapiens, human |
| Tissue | ovary |
| Cell Type | ovarian carcinoma |
| Product Format | frozen |
| Morphology | epithelial-like |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | papillary cystadenocarcinoma of the ovary |
| Gender | female |
| Applications | This cell line can be used to study resistance to microtubule stabilizing agents and other chemotherapy resistance mechanisms. |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | The parental cell line, HEY, was derived from a human ovarian cancer xenograft originally grown from a peritoneal sample from a patient with moderately differentiated papillary cystadenocarcinoma of the ovary. CRL-3252, HEY-T30, is a derivative of the HEY cell line and is resistant to Taxol. It was developed by exposure of its parental cell line, HEY, to stepwise escalating concentrations of Taxol over a 6-month period and it is maintained in medium containing 30 nmol/L Taxol. |
| Receptor Expression | Insulin-like growth factor 2 (IGF2; documented in PubMed 20404007) |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
|
| Subculturing | Note: Add Taxol to FBS-containing RPMI-1640 medium each time cells are fluid changed or manipulated. Volumes used in this subculture protocol are for a 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation ratio: A subcultivation ratio of 1:3 to 1:12 is recommended. Medium renewal: 2 to 3 times weekly |
| Culture Conditions | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile | Amelogenin: X CSF1PO: 10,11 D13S317: 11 D16S539: 8,12 D5S818: 11,12 D7S820: 12 THO1: 8,9.3 TPOX: 11 vWA: 16,17 |
| Population Doubling Time | 18-22 hours (in e-mail from Dr. Brouwer dated 12/02/14) |
| Name of Depositor | Jurriaan Brouwer-Visser Institution: Albert Einstein College of Medicine, Bronx, NY |
| Year of Origin | 2006 |
| References | Buick RN, et al. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45: 3668-3676, 1985. PubMed: 4016745 Huang GS, et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer Res. 16(11): 2999–3010, 2010. PubMed: 20404007 King ER, et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol. Oncol. 123(1): 13-18, 2011. PubMed: 21726895 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
